Corporate Development Lead (Associate Director)
Trillium Therapeutics is a clinical stage immuno-oncology company based in Cambridge, MA and Toronto, ON. Following recent promising clinical data updates and after raising over $300 million in 2020, the Company is now embarking on a substantial organizational scale-up to initiate a phase 2 program across a range of cancer indications. The Company is seeking a new Corporate Development Lead, who will play a significant role in Trillium’s strategy and business development activities. The position will report into the SVP Corporate Development and Strategy and will be based in Cambridge, MA.
Trillium Therapeutics (NASDAQ: TRIL) is a clinical stage biotechnology company developing next generation immunotherapies targeting CD47, a checkpoint of the innate immune system. Immunotherapy is a rapidly evolving field that is redefining cancer care by harnessing a patient’s own immune system to eliminate tumor cells. First generation immunotherapies, targeting the adaptive immune system via T cell checkpoint inhibitors, have been enormously successful scientifically (2018 Nobel Prize), clinically (achieving real cure rates), and commercially (soon to be the largest drug class ever). CD47 is now emerging as one of the most promising next generation immuno-oncology targets.
Trillium has two highly differentiated CD47 blockers in development that – unlike other CD47 agents – have shown unique monotherapy activity across a range of hematologic malignancies. Under new leadership, Trillium has undergone a wide-ranging transformation program, including a major strategy reset. In 2020, the company raised over $300M, secured a strategic investment from Pfizer, and has been among the top performers on NASDAQ. Nearing completion of ongoing dose escalation studies, Trillium is now scaling up its organization to initiate a phase 2 program across several cancer indications.
- Map the landscape of prioritized indications via primary and secondary, synthesize findings and draw out strategic implications. Keep abreast of changes in the industry and immunooncology, proactively identifying and assessing strategic business opportunities and issues
- Refine Trillium’s target product profiles, in close collaboration with the Corporate Development colleagues, Clinical colleagues and Trillium’s advisors
- Support Trillium’s strategic planning process, in close collaboration with the Executive Team and Board
- Collaborate to identify partnership opportunities, lead and coordinate diligence efforts. Analyze and perform scientific, clinical and regulatory assessments of external programs, assets, and companies. Coordinate and lead partnering diligence processes with appropriate rigor, transparency, diligence, and governance
- Support communications for corporate updates, investor relation events and other external presentations
- Work in compliance with Trillium’s Code of Business Conduct and all workplace policies, procedures and regulations
- Advanced scientific degree (MD, PhD, PharmD)
- Minimum three years’ work experience in biotech consulting, investment banking or within a biotech fund with excellent drug development knowledge; understanding of the Oncology therapeutic area preferred
- Previous experience collecting and tracking competitive intelligence
- Experience working in a matrix environment and partnering with functional experts
- Ability to rapidly synthesize information from multiple sources, communicate ideas and data both verbally and written format for a variety of audiences
- Ability to create and communicate key presentations to internal leadership and external partners with credibility and confidence
- Highly analytical and detail oriented
- Able to work across many interfaces (clinical/clinical operations, CMC, investor relations, project management, etc.)
- Demonstrated strong interpersonal skills, ability to influence, and the ability to function in a global team environment
- Strong and effective communication skills (written and verbal), with excellent medical/scientific writing skills
- Strong integrity and a commitment to improving patient outcomes
- Must be willing and able to be “hands-on”, and can thrive in a matrixed, fast-paced business environment
- Ability to work effectively with other company leaders and develop strong working relationships with them
- Once routine travel resumes, willingness and ability to travel up to 30% of time.